<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41032432</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1853-0605</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)</Title><ISOAbbreviation>Rev Fac Cien Med Univ Nac Cordoba</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>526</StartPage><EndPage>543</EndPage><MedlinePgn>526-543</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.31053/1853.0605.v82.n3.45772</ELocationID><Abstract><AbstractText>Introducci&#xf3;n: El COVID-19 afect&#xf3; diferencialmente a individuos con enfermedades cr&#xf3;nicas como c&#xe1;ncer, con mayor gravedad y mortalidad que la poblaci&#xf3;n general. Objetivos: Estimar incidencia de infecci&#xf3;n, internaci&#xf3;n y letalidad por COVID-19 en pacientes con c&#xe1;ncer diagnosticados entre el 1 de enero del 2018 y 31 de diciembre del 2020, atendidos en un Hospital de la ciudad de Mar del Plata y evaluar factores de riesgo de infecci&#xf3;n. M&#xe9;todos: estudio de cohorte retrospectivo en pacientes con c&#xe1;ncer de 15 a&#xf1;os o m&#xe1;s. Se relevaron variables demogr&#xe1;ficas, comorbilidades, caracter&#xed;sticas del tumor, tratamientos oncol&#xf3;gicos, infecci&#xf3;n, internaci&#xf3;n y fallecimiento por COVID-19. Se ajustaron curvas de Kaplan-Meier y un modelo de regresi&#xf3;n de Cox; la variable respuesta fue el tiempo hasta la infecci&#xf3;n. Resultados: Se incluyeron 995 pacientes, 8,9% tuvieron COVID-19. 95,6% presentaban tumores s&#xf3;lidos, 41.4% formas graves de c&#xe1;ncer, 1.7% m&#xe1;s de un tumor maligno y 10,9% tumores con formas metast&#xe1;sicas. Los pacientes menores de 60 a&#xf1;os, con c&#xe1;ncer hematol&#xf3;gico y/o formas graves de c&#xe1;ncer presentaron mayor riesgo de infecci&#xf3;n por COVID-19. Discusi&#xf3;n: La mayor circulaci&#xf3;n y exposici&#xf3;n en los menores de 60 a&#xf1;os podr&#xed;an explicar el mayor riesgo de infecci&#xf3;n, mientras que la disminuci&#xf3;n del estado inmunitario lo ser&#xed;a en el caso de los c&#xe1;nceres s&#xf3;lidos con estadios m&#xe1;s severos o los de tipo hematol&#xf3;gico.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bienaime</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiolog&#xed;a Dr. Jara. ANLIS Malbran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballejo</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiolog&#xed;a Dr. Jara. ANLIS Malbran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricardo</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiolog&#xed;a Dr. Jara. ANLIS Malbran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irassar</LastName><ForeName>Juan Ignacio</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiolog&#xed;a Dr. Jara. ANLIS Malbran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amezqueta</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiolog&#xed;a Dr. Jara. ANLIS Malbran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabuda</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiolog&#xed;a Dr. Jara. ANLIS Malbran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casatti</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital Interzonal General de Agudos Dr Oscar Alende, Mar del Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laspada</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital Interzonal General de Agudos Dr Oscar Alende, Mar del Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Interzonal General de Agudos Dr Oscar Alende, Mar del Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Maria Antonela</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Instituto Nacional del C&#xe1;ncer, Ministerio de Salud, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dana Smith</LastName><ForeName>Ramiro</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiolog&#xed;a Dr. Jara. ANLIS Malbran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Incidencia de COVID-19 en pacientes con c&#xe1;ncer del HIGA Alende, Mar del Plata, Argentina, 2020-2021.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Argentina</Country><MedlineTA>Rev Fac Cien Med Univ Nac Cordoba</MedlineTA><NlmUniqueID>8303003</NlmUniqueID><ISSNLinking>0014-6722</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001118" MajorTopicYN="N" Type="Geographic">Argentina</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41032432</ArticleId><ArticleId IdType="doi">10.31053/1853.0605.v82.n3.45772</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">41029603</PMID><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2458</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>BMC public health</Title><ISOAbbreviation>BMC Public Health</ISOAbbreviation></Journal><ArticleTitle>Social capital and its association with clinically significant depressive symptoms in patients with end-stage kidney disease in Mexico.</ArticleTitle><Pagination><StartPage>3182</StartPage><MedlinePgn>3182</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12889-025-24526-x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alanis-Oc&#xe1;diz</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Programa de Doctorado en Ciencias M&#xe9;dicas, Odontol&#xf3;gicas y de la Salud, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Av. Universidad 3004, Copilco Universidad, Coyoac&#xe1;n, Ciudad de M&#xe9;xico, 04510, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 9. OOAD Aguascalientes, Av. Siglo XXI LB Municipio libre CP 20199, Aguascalientes, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doubova</LastName><ForeName>Svetlana V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Unidad de Investigaci&#xf3;n en Epidemiologia y Servicios de Salud del Centro M&#xe9;dico Nacional Siglo XXI, Av. Cuauht&#xe9;moc 330, Col. Doctores, Cuauht&#xe9;moc, Ciudad de M&#xe9;xico, 06720, M&#xe9;xico. svetlana.doubova@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arreola-Guerra</LastName><ForeName>Jos&#xe9; Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Departamento de nefrolog&#xed;a del Centenario Hospital Miguel Hidalgo, Av. Manuel G&#xf3;mez Mor&#xed;n s/n, Alameda, 20259, Aguascalientes, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto para la Atenci&#xf3;n Integral de Enfermedades Renales del Estado de Aguascalientes, Av. Manuel G&#xf3;mez Mor&#xed;n s/n, Col. Alameda, Aguascalientes, 20259, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monroy</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital General de M&#xe9;xico "Dr. Eduardo Liceaga", Coordinaci&#xf3;n de Investigaci&#xf3;n en oncologia, Dr. Balmis 148, Col. Doctores, Cuauht&#xe9;moc, Ciudad de M&#xe9;xico, 06720, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bautista</LastName><ForeName>Humberto Mart&#xed;nez</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Matem&#xe1;ticas, A.C. (CIMAT), Unidad Aguascalientes, Calzada de la Plenitud 103, Fracc. Jos&#xe9; Vasconcelos, Mexico, CP 20200, Aguascalientes.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padilla-L&#xf3;pez</LastName><ForeName>Jannett</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Programa de Doctorado en Ciencias M&#xe9;dicas, Odontol&#xf3;gicas y de la Salud, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Av. Universidad 3004, Copilco Universidad, Coyoac&#xe1;n, Ciudad de M&#xe9;xico, 04510, M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 1. OOAD Aguascalientes, Av. Jos&#xe9; Mar&#xed;a Ch&#xe1;vez 1202, Lindavista, Aguascalientes, 20270, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qui&#xf1;ones-Villalobos</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Instituto para la Atenci&#xf3;n Integral de Enfermedades Renales del Estado de Aguascalientes, Av. Manuel G&#xf3;mez Mor&#xed;n s/n, Col. Alameda, Aguascalientes, 20259, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prado-Aguilar</LastName><ForeName>Carlos Alberto</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Coordinaci&#xf3;n M&#xe9;dica de investigaci&#xf3;n del Instituto Mexicano del Seguro Social OOAD Aguascalientes, Av. Jos&#xe9; Mar&#xed;a Ch&#xe1;vez 1202, Lindavista, Aguascalientes, 20270, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R-2022-785-053</GrantID><Agency>Research Funding Program of the Mexican Institute of Social Security as part of the 2023 IMSS Call for funding research projects focus on Priority Health issues, Vulnerable Populations and Emerging Issues.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Public Health</MedlineTA><NlmUniqueID>100968562</NlmUniqueID><ISSNLinking>1471-2458</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic kidney disease</Keyword><Keyword MajorTopicYN="N">Depressive symptoms</Keyword><Keyword MajorTopicYN="N">Mexico</Keyword><Keyword MajorTopicYN="N">Social capital</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The Instituto Mexicano del Seguro Social National Scientific Research and Ethics Committee approved the research protocol under registration number R-2022-785-053. The study was conducted in accordance with the Declaration of Helsinki. All patients who participated in the study signed informed consent before completing the survey. Consent for publication: Consent for publication was not required by the IMSS National Scientific Research and Ethics Committee. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>1</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41029603</ArticleId><ArticleId IdType="doi">10.1186/s12889-025-24526-x</ArticleId><ArticleId IdType="pii">10.1186/s12889-025-24526-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bello AK, Okpechi IG, Levin A, Ye F, Damster S, Arruebo S, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024;12(3):e382-95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(23)00570-3</ArticleId><ArticleId IdType="pubmed">38365413</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20:473&#x2013;85. https://doi.org/10.1038/s41581-024-00820-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-024-00820-6</ArticleId><ArticleId IdType="pubmed">38570631</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirazian S, Grant CD, Aina O, Mattana J, Khorassani F, Ricardo AC. Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep. 2017;2(1):94&#x2013;107. https://doi.org/10.1016/j.ekir.2016.09.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2016.09.005</ArticleId><ArticleId IdType="pubmed">29318209</ArticleId></ArticleIdList></Reference><Reference><Citation>4. Organizaci&#xf3;n Mundial de la Salud. Depresi&#xf3;n. 2023. https://www.who.int/es/news-room/fact-sheets/detail/depression. Accessed on 2025 Feb 24.</Citation></Reference><Reference><Citation>Adejumo OA, Edeki IR, Sunday Oyedepo D, Falade J, Yisau OE, Ige OO, et al. Global prevalence of depression in chronic kidney disease: a systematic review and meta-analysis. J Nephrol. 2024;37(9):2455&#x2013;72. https://doi.org/10.1016/j.ekir.2016.09.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2016.09.005</ArticleId><ArticleId IdType="pubmed">38954184</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C-H, Fan P-C, Kuo G, Lin Y-S, Tsai T-Y, Chang S-W, et al. Infection in advanced chronic kidney disease and subsequent adverse outcomes after dialysis initiation: a nationwide cohort study. Sci Rep. 2020;10(1):2938. https://doi.org/10.1038/s41598-020-59794-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-59794-7</ArticleId><ArticleId IdType="pubmed">32076027</ArticleId><ArticleId IdType="pmc">7031239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigami J, Matsushita K. Clinical epidemiology of infectious disease among patients with chronic kidney disease. Clin Exp Nephrol. 2019;23(4):437&#x2013;47. https://doi.org/10.1007/s10157-018-1641-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10157-018-1641-8</ArticleId><ArticleId IdType="pubmed">30178234</ArticleId></ArticleIdList></Reference><Reference><Citation>Kistler BM, Khubchandani J, Bennett P, Wilund KR, Sosnoff J. Depressive disorders are associated with risk of falls in people with chronic kidney disease. J Am Psychiatr Nurses Assoc. 2022;28(3):235&#x2013;40. https://doi.org/10.1177/1078390320970648 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1078390320970648</ArticleId><ArticleId IdType="pubmed">33150807</ArticleId></ArticleIdList></Reference><Reference><Citation>Young BA, Von Korff M, Heckbert SR, Ludman EJ, Rutter C, Lin EHB, et al. Association of major depression and mortality in Stage 5 diabetic chronic kidney disease. Gen Hosp Psychiatry. 2010;32(2):119&#x2013;24. https://doi.org/10.1016/j.genhosppsych.2009.11.018 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genhosppsych.2009.11.018</ArticleId><ArticleId IdType="pubmed">20302984</ArticleId><ArticleId IdType="pmc">3488265</ArticleId></ArticleIdList></Reference><Reference><Citation>Chilcot J, Davenport A, Wellsted D, Firth J, Farrington K. An association between depressive symptoms and survival in incident dialysis patients. Nephrology Dialysis Transplantation. 2011;26(5):1628&#x2013;34. https://doi.org/10.1093/ndt/gfq611 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfq611</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal HK, Jain D, Dabas G, Yadav RK. Prevalence of depression, anxiety and insomnia in chronic kidney disease patients and their co-relation with the demographic variables. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017;38(2):35&#x2013;44. https://doi.org/10.1515/prilozi-2017-0020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/prilozi-2017-0020</ArticleId><ArticleId IdType="pubmed">28991772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlawat R, Tiwari P, D&#x2019;cruz S. Renal data from Asia-Africa prevalence of depression and its associated factors among patients of chronic kidney disease in a public tertiary care hospital in India: A Cross-sectional Study. Saudi J Kidney Dis Transpl. 2018;29:1165&#x2013;73. https://doi.org/10.4103/1319-2442.243972 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1319-2442.243972</ArticleId><ArticleId IdType="pubmed">30381514</ArticleId></ArticleIdList></Reference><Reference><Citation>13. Pu L, Zou Y, Wu S kun, Wang F, Zhang Y, Li G sen, et al. Prevalence and associated factors of depressive symptoms among chronic kidney disease patients in China: Results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). J Psychosom Res. 2020;128:109869. https://doi.org/10.1016/j.jpsychores.2019.109869</Citation></Reference><Reference><Citation>14. Araujo SMHA, De Bruin VMS, De F. Daher E, Almeida GH, Medeiros CAM, De Bruin PFC. Risk factors for depressive symptoms in a large population on chronic hemodialysis. Int Urol Nephrol. 2012;44(4):1229&#x2013;35. https://doi.org/10.1007/s11255-011-0032-9</Citation></Reference><Reference><Citation>15. Putnam RD, Leonardi R, Nanetti RY. Making Democracy work: Civic Traditions in Modern Italy. Princeton University Press; 1994 https://doi.org/10.1007/s11255-011-0032-9</Citation></Reference><Reference><Citation>16. Solar O, Irwin A. A conceptual framework for action on the social determinants of health. Social Determinants of Health Discussion Paper 2 (Policy and Practice). Geneva: World Health Organization;2010. Available from: https://iris.who.int/bitstream/handle/10665/44489/9789241500852_eng.pdf?sequence=1 Accessed on 2025 Feb 24</Citation></Reference><Reference><Citation>17. Rocco L, Suhrcke M. Is social capital good for health? A European perspective. EuroWhoInt. 2012:1&#x2013;24. Available from: https://iris.who.int/handle/10665/352821</Citation></Reference><Reference><Citation>18. Kawachi I, Subramanian SV KD. Social capital and health. New York: Springer Science; 2010.</Citation></Reference><Reference><Citation>19. Berkman LF, Kawachi I. Social Capital, Social Cohesion, and Health. In: Berkman L, Kawachi I, Glymour. M. M., editors. Social Epidemiology. New York, NY. United States of America: Oxford University Press; 2014.</Citation></Reference><Reference><Citation>Do AD, Pham TTP, Nguyen CQ, Van Hoang D, Fukunaga A, Stickley A, et al. Individual-level social capital is associated with depressive symptoms among middle-aged community dwellers in rural Vietnam: a cross-sectional study. BMJ Open. 2022;12(12). https://doi.org/10.1136/bmjopen-2022-064998 .</Citation></Reference><Reference><Citation>Zhou S, Li K, Ogihara A, Wang X. Association between social capital and depression among older adults of different genders: Evidence from Hangzhou. China Front Public Health. 2022;10:63574. https://doi.org/10.3389/fpubh.2022.863574 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.863574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao S, Chen J. Neighborhood-based social capital and depressive symptoms among adults: evidence from Guangzhou, China. Int J Environ Res Public Health. 2021;18(21):11263. https://doi.org/10.3390/ijerph182111263 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph182111263</ArticleId><ArticleId IdType="pubmed">34769781</ArticleId><ArticleId IdType="pmc">8582690</ArticleId></ArticleIdList></Reference><Reference><Citation>23. Li H, Xia H, Yi S, Rao L. Social capital, depressive symptoms, and perceived quality of care among hypertensive patients in primary care. Health Qual Life Outcomes. 2020;18(1). https://doi.org/10.1186/s12955-020-01630-7</Citation></Reference><Reference><Citation>Zhang Y, Li J, Fang F, Fu W. Association between social capital and depression among critically ill patients: evidence from a cross-sectional study in rural Shandong, China. BMC Psychiatry. 2021;21(1):471. https://doi.org/10.1186/s12888-021-03476-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-021-03476-9</ArticleId><ArticleId IdType="pubmed">34579705</ArticleId><ArticleId IdType="pmc">8474862</ArticleId></ArticleIdList></Reference><Reference><Citation>Souto EP, Moreno AB, Chor D, Melo ECP, Barreto SM, Nunes MA, et al. Social Capital and Depressive Episodes: Gender Differences in the ELSA-Brasil Cohort. Front Public Health. 2021;9. https://doi.org/10.3389/fpubh.2021.657700 .</Citation></Reference><Reference><Citation>26. Kemppainen J, Timonen M. Social Capital and Depressive Symptoms: A Systematic Review. J Theor Soc Psychol. 2024;2024(1). https://doi.org/10.1155/jts5/3278094</Citation></Reference><Reference><Citation>27. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990&#x2013;2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100&#x2013;2132. https://doi.org/10.1016/S0140-6736(24)00367-2</Citation></Reference><Reference><Citation>28. Argaiz ER, Morales-Ju&#xe1;rez L, Razo C, Ong L, Rafferty Q, Rinc&#xf3;n-Pedrero R, et al. The burden of chronic kidney disease in Mexico. Data analysis based on the Global Burden of Disease 2021 study. Gac Med Mex. 2024;159(6):487&#x2013;493. https://doi.org/10.24875/GMM.M24000830</Citation></Reference><Reference><Citation>Gonz&#xe1;lez-De-Jes&#xfa;s LN, S&#xe1;nchez-Rom&#xe1;n S, Morales-Buenrostro LE, Ostrosky-Sol&#xed;s F, Alber&#xfa; J, Garc&#xed;a-Ramos G, et al. Assessment of emotional distress in chronic kidney disease patients and kidney transplant recipients. Rev Invest Clin. 2011;63:558&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">23650668</ArticleId></ArticleIdList></Reference><Reference><Citation>Murillo-Zamora E. Mac&#xed;as-de la Torre AA, Higareda-Almaraz MA [Depression prevalence among end stage renal disease patients in maintenance hemodialysis]. Rev Med Inst Mex Seguro Soc. 2016;54:429&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">27197098</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Flores CJ, Garc&#xed;a-Garc&#xed;a G, Lerma A, P&#xe9;rez-Grovas H, Meda-Lara RM, Guzm&#xe1;n-Salda&#xf1;a RME, et al. Resilience: A Protective Factor from Depression and Anxiety in Mexican Dialysis Patients. Int J Environ Res Public Health. 2021;18:11957. https://doi.org/10.3390/ijerph182211957 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph182211957</ArticleId><ArticleId IdType="pubmed">34831713</ArticleId><ArticleId IdType="pmc">8620979</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer S, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84(1):179&#x2013;91. https://doi.org/10.1038/ki.2013.77 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2013.77</ArticleId><ArticleId IdType="pubmed">23486521</ArticleId></ArticleIdList></Reference><Reference><Citation>33. Freeman DH. Applied categorical data analysis. New York: Marcel Dekker Inc; 1987.</Citation></Reference><Reference><Citation>Alanis-Oc&#xe1;diz A, Doubova SV, Arreola-Guerra JM, Monroy A, Padilla-L&#xf3;pez J, Qui&#xf1;ones-Villalobos C, et al. Design and psychometric validation of a social capital questionnaire for adults with end-stage chronic kidney disease undergoing dialysis or hemodialysis. BMC Nephrol. 2025;26(1):105. https://doi.org/10.1186/s12882-025-03993-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-025-03993-9</ArticleId><ArticleId IdType="pubmed">40021955</ArticleId><ArticleId IdType="pmc">11871631</ArticleId></ArticleIdList></Reference><Reference><Citation>35. Rosas-Santiago FJ, Rodr&#xed;guez-Perez V, Dianeth Hern&#xe1;ndez-Aguilera R, Lagunes C&#xf3;rdoba R. Factorial structure of Mexican version of the Beck Depression Inventory II in general population of Mexican Southeastern. Salud, Barranquilla. 2020;36(2):436&#x2013;449. https://doi.org/10.14482/sun.36.2.616.85.</Citation></Reference><Reference><Citation>36. Asociaci&#xf3;n Mexicana de Agencias de Inteligencia de Mercado y Opini&#xf3;n (AMAI). Descripci&#xf3;n de los Niveles Socioecon&#xf3;micos. Estimaci&#xf3;n 2024. Available from: https://www.amai.org/NSE/index.php?queVeo=niveles. Accessed on 2025 Apr 26.</Citation></Reference><Reference><Citation>37. Kovesdy CP, Kalantar-Zadeh K. Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology (Carlton). 2009;14(4):408&#x2013;415. https://doi.org/10.1111/j.1440-1797.2009.01119.x</Citation></Reference><Reference><Citation>Alhazmi AI, Alghamdi AM, Alghamdi FS, Alhumam MN, Alghamdi MKN, Alghamdi GA, Jathmi SAS. Association of Hyperparathyroidism with Depression and Anxiety Among Chronic Hemodialysis Patients in the Al Baha Region, Kingdom of Saudi Arabia. Cureus. 2024;16(3). https://doi.org/10.7759/cureus.57210 .</Citation></Reference><Reference><Citation>39. Editorial Office, E. Social Group. Encyclopedia. Available from: https://encyclopedia.pub/entry/54088. Accessed on 2024 May 20</Citation></Reference><Reference><Citation>Yang H, Qi L, Pei D. Effect of psychosocial interventions for depression in adults with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2024;25(1):17. https://doi.org/10.1186/s12882-023-03447-0 .</Citation></Reference><Reference><Citation>41. Missikpode C, Ricardo AC, Brown J, Durazo-Arvizi RA, Fischer MJ, Hernandez R, et al. Association between Depressive Symptom Trajectory and Chronic Kidney Disease Progression: Findings from the Chronic Renal Insufficiency Cohort Study. Kidney360. 2023;4(5):606&#x2013;14. https://doi.org/10.34067/KID.0000000000000087</Citation></Reference><Reference><Citation>Hernandez R, Xie D, Wang X, Jordan N, Ricardo AC, Anderson AH, et al. Depressive symptoms, antidepressants, and clinical outcomes in chronic kidney disease: findings from the CRIC study. Kidney Med. 2024;6(4). https://doi.org/10.1016/j.xkme.2024.100790 .</Citation></Reference><Reference><Citation>Pearce CJ, Hall N, Hudson JL, Farrington K, Tucker MJR, Wellsted D, et al. Approaches to the identification and management of depression in people living with chronic kidney disease: A scoping review of 860 papers. J Ren Care. 2024;50(1):4&#x2013;14. https://doi.org/10.1111/jorc.12458 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jorc.12458</ArticleId><ArticleId IdType="pubmed">36645375</ArticleId></ArticleIdList></Reference><Reference><Citation>Bautovich A, Katz I, Loo CK, Harvey SB. Beck Depression Inventory as a screening tool for depression in chronic haemodialysis patients. Australasian Psychiatry. 2018;26(3):281&#x2013;4. https://doi.org/10.1177/1039856218758 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1039856218758</ArticleId><ArticleId IdType="pubmed">29457471</ArticleId></ArticleIdList></Reference><Reference><Citation>Preljevic VT, &#xd8;sthus TBH, Sandvik L, Opjordsmoen S, Nordhus IH, Os I, et al. Screening for anxiety and depression in dialysis patients: Comparison of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory. J Psychosom Res. 2012;73(2):139&#x2013;434. https://doi.org/10.1016/j.jpsychores.2012.04.015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2012.04.015</ArticleId><ArticleId IdType="pubmed">22789418</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S, Lash TL, Rothman KJ. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams &amp; Wilkins; 2013. p. 641&#x2013;6.</Citation></Reference><Reference><Citation>Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3(1):21. https://doi.org/10.1186/1471-2288-3-21 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-3-21</ArticleId><ArticleId IdType="pubmed">14567763</ArticleId><ArticleId IdType="pmc">521200</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele TJ, Shpitser I. A New Criterion for Confounder Selection. Biometrics. 2011;67(4):1406&#x2013;13. https://doi.org/10.1111/j.1541-0420.2011.01619.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1541-0420.2011.01619.x</ArticleId><ArticleId IdType="pubmed">21627630</ArticleId><ArticleId IdType="pmc">3166439</ArticleId></ArticleIdList></Reference><Reference><Citation>Birditt KS, Turkelson A, Fingerman KL, Polenick CA, Oya A. Age differences in stress, life changes, and social ties during the COVID-19 pandemic: implications for psychological well-being. Gerontologist. 2021;61(2):205&#x2013;16. https://doi.org/10.1093/geront/gnaa204 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/geront/gnaa204</ArticleId><ArticleId IdType="pubmed">33346806</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamine S, Tachikawa H, Aiba M, Takahashi S, Noguchi H, Takahashi H, et al. Changes in social capital and depressive states of middle-aged adults in Japan. PLoS One. 2017;12(12). https://doi.org/10.1371/journal.pone.0189112 .</Citation></Reference><Reference><Citation>Qu T. A bridge too far? Social network structure as a determinant of depression in later life. Soc Sci Med. 2024;345. https://doi.org/10.1016/j.socscimed.2024.116684 .</Citation></Reference><Reference><Citation>Putnam RD. Bowling Alone: The Collapse and Revival of American Community. New York: Simon &amp; Schuster; 2000.</Citation></Reference><Reference><Citation>De Silva MJ, McKenzie K, Harpham T, Huttly SRA. Social capital and mental illness: A systematic review. J Epidemiol Community Health. 2005;59(8):619&#x2013;27. https://doi.org/10.1136/jech.2004.029678 .</Citation></Reference><Reference><Citation>Bai Z, Yang J, Wang Z, Cao W, Cao C, Hu Z, et al. Association between social capital and self-rated health among community-dwelling older adults. Front Public Health. 2022;10:916485. https://doi.org/10.3389/fpubh.2022.916485 .</Citation></Reference><Reference><Citation>Bai Z, Xu Z, Xu X, Qin X, Hu W, Hu Z. Association between social capital and depression among older people: evidence from Anhui Province, China. BMC Public Health. 2020;20(1):1560. https://doi.org/10.1186/s12889-020-09657-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-09657-7</ArticleId><ArticleId IdType="pubmed">33066764</ArticleId><ArticleId IdType="pmc">7565750</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe J, Kimura T, Nakamura T, Suzuki D, Takemoto T, Tamakoshi A. Associations of social capital and health at a city with high aging rate and low population density. SSM Popul Health. 2022;17:100981. https://doi.org/10.1016/j.ssmph.2021.100981 .</Citation></Reference><Reference><Citation>Mao S, Lu N, Xiao C. Perceived neighborhood environment and depressive symptoms among older adults living in Urban China: The mediator role of social capital. Health Soc Care Community. 2022;30(5):e1977&#x2013;90. https://doi.org/10.1111/hsc.13631 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hsc.13631</ArticleId><ArticleId IdType="pubmed">34725894</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr KA. A cohort longitudinal study of individual level social capital and depressive symptoms in the Wisconsin Longitudinal Study. SSM Popul Health. 2020;10:100544. https://doi.org/10.1016/j.ssmph.2020.100544 .</Citation></Reference><Reference><Citation>Abreu TC, Mackenbach JD, Beulens JWJ, Vaartjes I, Kawachi I. Family is all that matters: Prospective associations between structure, function, and quality of social relations and self-rated health in the National Social Life, Health, and Aging Project (NSHAP). SSM Popul Health. 2024;28:.101715. https://doi.org/10.1016/j.ssmph.2024.101715 .</Citation></Reference><Reference><Citation>Holt-Lunstad J. Social Connection as a Public Health Issue: The Evidence and a Systemic Framework for Prioritizing the &#x201c;Social&#x201d; in Social Determinants of Health. Annu Rev Public Health. 2022;43(1):193&#x2013;213. https://doi.org/10.1146/annurev-publhealth-052020-110732 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-publhealth-052020-110732</ArticleId><ArticleId IdType="pubmed">35021021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugur ZB. How does Inequality Hamper Subjective Well-being? The Role of Fairness. Soc Indic Res. 2021;158(2):377&#x2013;407. https://doi.org/10.1007/s11205-021-02711-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11205-021-02711-w</ArticleId><ArticleId IdType="pubmed">34025004</ArticleId><ArticleId IdType="pmc">8122217</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkbride JB, Anglin DM, Colman I, Dykxhoorn J, Jones PB, Patalay P, et al. The social determinants of mental health and disorder: evidence, prevention and recommendations. World Psychiatry. 2024;23(1):58&#x2013;90. https://doi.org/10.1002/wps.21160 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wps.21160</ArticleId><ArticleId IdType="pubmed">38214615</ArticleId><ArticleId IdType="pmc">10786006</ArticleId></ArticleIdList></Reference><Reference><Citation>63. Eriksson M. Social capital and health&#x2013;implications for health promotion. Glob Health Action. 2011;4:5611. https://doi.org/10.3402/gha.v4i0.5611</Citation></Reference><Reference><Citation>Gutierrez-Pe&#xf1;a M, Zu&#xf1;iga-Macias L, Marin-Garcia R, Ovalle-Robles I, Garc&#xed;a-D&#xed;az AL, Mac&#xed;as-Guzm&#xe1;n MJ, et al. High prevalence of end-stage renal disease of unknown origin in Aguascalientes Mexico: role of the registry of chronic kidney disease and renal biopsy in its approach and future directions. Clin Kidney J. 2021;14:1197&#x2013;206. https://doi.org/10.1093/ckj/sfaa229 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfaa229</ArticleId><ArticleId IdType="pubmed">34094519</ArticleId><ArticleId IdType="pmc">8173605</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41018707</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Effectiveness and Safety of Antibiotics in Kidney Transplant Recipients With Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis of Randomized Controlled Trials.</ArticleTitle><Pagination><StartPage>ofaf502</StartPage><MedlinePgn>ofaf502</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofaf502</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofaf502</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Asymptomatic bacteriuria (ASB) is generally systematically screened and treated with antibiotics in kidney transplant recipients (KTRs). We aimed to explore the role of antibiotic therapy in management of ASB in KTRs.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Randomized controlled trials conducted through 10 May 2023 were searched on Ovid MEDLINE, Web of Science, PubMed, and Cochrane CENTRAL. We used inverse variance random-effects models for all meta-analyses; for rare outcomes, we used the Mantel-Haenszel method. ROB-2 criteria were used to assess the risk of bias.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We identified 4 randomized controlled trials (including 478 participants). Antibiotic therapy, compared with no therapy, nonsignificantly increased the risk of acute pyelonephritis by 19% (relative risk, 1.19 [95% confidence interval (CI)], .72-1.94; <i>I</i> <sup>2</sup> = 0%) and that of symptomatic urinary tract infection (UTI) by 18% (1.18 [.78-1.78]; <i>I</i> <sup>2</sup> = 28%). The risks of all-cause mortality (relative risk, 1.56 [95% CI, .54-4.52]), graft loss (0.80 [.20-3.19]), graft rejection (0.89 [.46-1.70]), hospital admission due to symptomatic UTI (0.92 [.48-1.76]), symptomatic UTI caused by a multidrug-resistant organism (1.31 [.63-2.74]), <i>Clostridioides difficile</i> diarrhea (0.75 [.23-2.42]), and serious adverse events (1.20 [.75-1.91]) did not differ significantly between groups, nor did the change in serum creatinine level from baseline to the end of the study (mean difference, 0.40&#x2005;mg/dL [95% CI, -.05 to .85 mg/dL]). No significant differences were demonstrated in any outcomes between antibiotic therapy and no-therapy arms across subgroup and sensitivity analyses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Current evidence does not support routine screening and treatment of posttransplant ASB in KTRs.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aslan</LastName><ForeName>Abdullah Tarik</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, UQ Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanriverdi</LastName><ForeName>Lokman Hekim</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0003-4263-5234</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Medical Pharmacology, In&#xf6;n&#xfc; University, Malatya, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Adrian V</ForeName><Initials>AV</Initials><Identifier Source="ORCID">0000-0002-9999-4003</Identifier><AffiliationInfo><Affiliation>Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Revisiones Sistem&#xe1;ticas y Meta-An&#xe1;lisis (URSIGET), Vicerrectorado de Investigaci&#xf3;n, Universidad San Ignacio de Loyola, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akova</LastName><ForeName>Umut</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-1768-0503</Identifier><AffiliationInfo><Affiliation>Emory University School of Medicine, Faculty of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kutluca</LastName><ForeName>Kursat</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0000-9285-5863</Identifier><AffiliationInfo><Affiliation>School of Medicine, Hacettepe University, Ankara, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coussement</LastName><ForeName>Julien</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4302-6599</Identifier><AffiliationInfo><Affiliation>Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Guadeloupe, Les Abymes, Guadeloupe, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manuel</LastName><ForeName>Arreola Guerra Jose</ForeName><Initials>AGJ</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Hospital Centenario Miguel Hidalgo, Aguascalientes, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Atenci&#xf3;n Integral de Enfermedades Renales del Estado Aguascalientes, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orig&#xfc;en</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6507-0363</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Universitario "12 de Octubre," &#xa0;Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, Hospital Cl&#xed;nico Universitario "Lozano Blesa," &#xa0;Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sab&#xe9;</LastName><ForeName>N&#xfa;ria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Patrick N A</ForeName><Initials>PNA</Initials><Identifier Source="ORCID">0000-0002-2895-0345</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, UQ Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akova</LastName><ForeName>Murat</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6904-9473</Identifier><AffiliationInfo><Affiliation>School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Hacettepe University, Ankara, Turkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paterson</LastName><ForeName>David L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0003-2079-4437</Identifier><AffiliationInfo><Affiliation>ADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antibiotic</Keyword><Keyword MajorTopicYN="N">asymptomatic bacteriuria</Keyword><Keyword MajorTopicYN="N">kidney transplantation</Keyword><Keyword MajorTopicYN="N">pyelonephritis</Keyword><Keyword MajorTopicYN="N">urinary tract infection</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. P. N. A. H. reports a research grant from Gilead; has served on advisory boards for OpGen, Merck, and Sandoz; and has received speakers fees from OpGen, Sandoz, Pfizer, and bioMerieux. M. A. reports research support from Pfizer and Gilead and was also a member of a GSK data review committee. D. L. P. reports receiving grants from Shionogi, Pfizer, Merck, BioVersys, bioMerieux, Johnson &amp; Johnson, and Gilead and honoraria from Shionogi, Merck, GSK, bioMerieux, Cepheid, Aurobac, Arrepath, Menarini, CARB-X, and the AMR Action Fund. All other authors report no potential conflicts. Funding to pay the Open Access publication charges for this article was provided by The University of Queensland.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>13</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>13</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41018707</ArticleId><ArticleId IdType="pmc">PMC12461846</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofaf502</ArticleId><ArticleId IdType="pii">ofaf502</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fiorante &#xa0;S, Fern&#xe1;ndez-Ruiz &#xa0;M, L&#xf3;pez-Medrano &#xa0;F, et al. &#xa0;Acute graft pyelonephritis in renal transplant recipients: incidence, risk factors and long-term outcome. Nephrol Dial Transplant &#xa0;2011; 26:1065&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">20805254</ArticleId></ArticleIdList></Reference><Reference><Citation>Valera &#xa0;B, Gentil &#xa0;MA, Cabello &#xa0;V, Fijo &#xa0;J, Cordero &#xa0;E, Cisneros &#xa0;JM. Epidemiology of urinary infections in renal transplant recipients. Transplant Proc &#xa0;2006; 38:2414&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17097953</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao &#xa0;Z, Wang &#xa0;Z, Tang &#xa0;M, Shen &#xa0;L, Zhang &#xa0;K. Treatment of asymptomatic bacteriuria after kidney transplantation: a systematic review and meta-analysis of randomized controlled trials. Medicina &#xa0;2023; 59:1600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10535591</ArticleId><ArticleId IdType="pubmed">37763718</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasuraman &#xa0;R, Julian &#xa0;K; AST Infectious Diseases Community of Practice . Urinary tract infections in solid organ transplantation. Am J Transplant &#xa0;2013; 13(suppl 4):327&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">23465025</ArticleId></ArticleIdList></Reference><Reference><Citation>Coussement &#xa0;J, Maggiore &#xa0;U, Manuel &#xa0;O, et al. &#xa0;Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. Nephrol Dial Transplant &#xa0;2018; 33:1661&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29635410</ArticleId></ArticleIdList></Reference><Reference><Citation>Coussement &#xa0;J, Scemla &#xa0;A, Abramowicz &#xa0;D, Nagler &#xa0;EV, Webster &#xa0;AC. Antibiotics for asymptomatic bacteriuria in kidney transplant recipients. Cochrane Database Syst Rev &#xa0;2018; 2:CD011357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491324</ArticleId><ArticleId IdType="pubmed">29390169</ArticleId></ArticleIdList></Reference><Reference><Citation>Sab&#xe9; &#xa0;N, Cruzado &#xa0;JM, Carratal&#xe0; &#xa0;J. Asymptomatic bacteriuria in kidney transplant recipients: to treat or not to treat&#x2014;that is the question. Clin Microbiol Infect &#xa0;2021; 27:319&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">33276138</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina-Polo &#xa0;J, Falkensammer &#xa0;E, K&#xf6;ves &#xa0;B, et al. &#xa0;Systematic review and meta-analysis provide no guidance on management of asymptomatic bacteriuria within the first year after kidney transplantation. Antibiotics &#xa0;2024; 13:442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11117648</ArticleId><ArticleId IdType="pubmed">38786170</ArticleId></ArticleIdList></Reference><Reference><Citation>Page &#xa0;MJ, McKenzie &#xa0;JE, Bossuyt &#xa0;PM, et al. &#xa0;The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ &#xa0;2021; 372:n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolle &#xa0;LE, Bradley &#xa0;S, Colgan &#xa0;R, et al. &#xa0;Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis &#xa0;2005; 40:643&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">15714408</ArticleId></ArticleIdList></Reference><Reference><Citation>Coussement &#xa0;J, Kamar &#xa0;N, Matignon &#xa0;M, et al. &#xa0;Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomized, controlled trial. Clin Microbiol Infect &#xa0;2021; 27:398&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">32919076</ArticleId></ArticleIdList></Reference><Reference><Citation>Sab&#xe9; &#xa0;N, Oriol &#xa0;I, Melilli &#xa0;E, et al. &#xa0;Antibiotic treatment versus no treatment for asymptomatic bacteriuria in kidney transplant recipients: a multicenter randomized trial. Open Forum Infect Dis &#xa0;2019; 6:ofz243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6563942</ArticleId><ArticleId IdType="pubmed">31214630</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonio &#xa0;MEE, Cassandra &#xa0;BGC, Emiliano &#xa0;RJD, et al. &#xa0;Treatment of asymptomatic bacteriuria in the first 2 months after kidney transplant: a controlled clinical trial. Transpl Infect Dis &#xa0;2022; 24:e13934.</Citation><ArticleIdList><ArticleId IdType="pubmed">35980169</ArticleId></ArticleIdList></Reference><Reference><Citation>Orig&#xfc;en &#xa0;J, L&#xf3;pez-Medrano &#xa0;F, Fern&#xe1;ndez-Ruiz &#xa0;M, et al. &#xa0;Should asymptomatic bacteriuria be systematically treated in kidney transplant recipients? Results from a randomized controlled trial. Am J Transplant &#xa0;2016; 16:2943&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">27088545</ArticleId></ArticleIdList></Reference><Reference><Citation>Magiorakos &#xa0;AP, Srinivasan &#xa0;A, Carey &#xa0;RB, et al. &#xa0;Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect &#xa0;2012; 18:268&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">21793988</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne &#xa0;JAC, Savovi&#x107; &#xa0;J, Page &#xa0;MJ, et al. &#xa0;Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ &#xa0;2019; 366:l4898.</Citation><ArticleIdList><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Balshem &#xa0;H, Helfand &#xa0;M, Sch&#xfc;nemann &#xa0;HJ, et al. &#xa0;GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol &#xa0;2011; 64:401&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208779</ArticleId></ArticleIdList></Reference><Reference><Citation>
GRADEpro . GDT GRADEpro guideline development tool [software]. Hamilton, ON: McMaster University; 2020. Available at: http://www.gradepro.org. Accessed January 12, 2025.</Citation></Reference><Reference><Citation>Tolkoff-Rubin &#xa0;NE, Cosimi &#xa0;AB, Russell &#xa0;PS, Rubin &#xa0;RH. A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. Clin Infect Dis &#xa0;1982; 4:614&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7051249</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott &#xa0;KC, Swanson &#xa0;SJ, Richter &#xa0;ER, et al. &#xa0;Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis &#xa0;2004; 44:353&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264195</ArticleId></ArticleIdList></Reference><Reference><Citation>Green &#xa0;H, Rahamimov &#xa0;R, Gafter &#xa0;U, Leibovitci &#xa0;L, Paul &#xa0;M. Antibiotic prophylaxis for urinary tract infections in renal transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis &#xa0;2011; 13:441&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21521435</ArticleId></ArticleIdList></Reference><Reference><Citation>Amari EB &#xa0;E, Hadaya &#xa0;K, B&#xfc;hler &#xa0;L, et al. &#xa0;Outcome of treated and untreated asymptomatic bacteriuria in renal transplant recipients. Nephrol Dial Transplant &#xa0;2011; 26:4109&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">21592976</ArticleId></ArticleIdList></Reference><Reference><Citation>Green &#xa0;H, Rahamimov &#xa0;R, Goldberg &#xa0;E, et al. &#xa0;Consequences of treated versus untreated asymptomatic bacteriuria in the first year following kidney transplantation: retrospective observational study. Eur J Clin Microbiol Infect Dis &#xa0;2013; 32:127&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">22918514</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman &#xa0;JD, Julian &#xa0;K. Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant &#xa0;2019; 33:e13507.</Citation><ArticleIdList><ArticleId IdType="pubmed">30793386</ArticleId></ArticleIdList></Reference><Reference><Citation>Kranz &#xa0;J, Bartoletti &#xa0;R, Bruy&#xe8;re &#xa0;F, et al. &#xa0;European Association of Urology guidelines on urological infections: summary of the 2024 guidelines. Eur Urol &#xa0;2024; 86:27&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">38714379</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson &#xa0;Z, Aslan &#xa0;AT, Beahm &#xa0;NP, et al. &#xa0;Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines Group consensus statement. JAMA Netw Open &#xa0;2024; 7:e2444495.</Citation><ArticleIdList><ArticleId IdType="pubmed">39495518</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40990115</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Development and initial content validation of a new version of the damage index in thrombotic antiphospholipid syndrome (DIAPSV2).</ArticleTitle><Pagination><StartPage>9612033251379310</StartPage><MedlinePgn>9612033251379310</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033251379310</ELocationID><Abstract><AbstractText>BackgroundAntiphospholipid syndrome (APS) is the most common acquired hypercoagulable disorder characterized mainly by thrombotic events and obstetric morbidity. Quantifying chronic damage caused by APS is crucial for patient management. The original Damage Index for Thrombotic APS (DIAPS) was developed to address this need, but required updates to improve its comprehensiveness and specificity.ObjectiveTo report the initial content validation process of a new version of the damage index: DIAPSv2.MethodsA modified Delphi panel was conducted in two stages. Stage 1 involved a systematic scoping review of DIAPS studies, with data extracted from questionnaires and confirmed by the leading committee. These questionnaires identified items from the original instrument that needed modification, elimination, or replacement with new candidate items. Stage 2 employed the modified Delphi method over three rounds, considering expert panelists' opinions to select concepts for inclusion in DIAPSv2.ResultsIn Stage 1, evidence supported the validity of the original DIAPS but highlighted missing conditions reflecting chronic damage, such as alveolar hemorrhage and significant bleeding due to anticoagulation therapy. In Stage 2, participants from different working groups reached a consensus to evaluate 41 of the 67 items that the leading committee proposed for accurately measuring chronic damage in APS. A final consensus included 32 items. Definitions of all items were updated according to specialists' input and international recommendations for each domain.ConclusionsA collaborative and multidisciplinary consensus-based approach developed a new version of the damage index, comprising 11 domains and 32 items (an update from 10 domains and 38 items in the original version). DIAPSv2 offers a more specific tool for evaluating irreversible damage in patients with thrombotic APS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goycochea Robles</LastName><ForeName>Mar&#xed;a Victoria</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Gabriela Medina</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0002-5891-8653</Identifier><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n en Medicina Traslacional en Enfermedades Hematooncol&#xf3;gicas. Hospital de Especialidades Centro M&#xe9;dico La Raza Centro M&#xe9;dico La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendoza Pinto</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hospital de Especialidades, UMAE-Centro M&#xe9;dico Nacional, Manuel &#xc1;vila Camacho, Centro de Investigaci&#xf3;n Biom&#xe9;dica de Oriente, Puebla, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercado</LastName><ForeName>Claudia Mel&#xe9;ndez</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Centro M&#xe9;dico ISSEMYN Toluca Edo Mex, Toluca, Estado de M&#xe9;xico, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez Mart&#xed;nez</LastName><ForeName>Laura Aline</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Rheumatology Departament, Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Secretar&#xed;a de Salud, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medina San Mill&#xe1;n</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Rheumatology Departament, Hospital Ju&#xe1;rez de M&#xe9;xico Secretar&#xed;a de Salud, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzm&#xe1;n V&#xe1;zquez</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>HS Estudios Farmacoecon&#xf3;micos, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez Ruiz</LastName><ForeName>Ang&#xe9;lica Aurora</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Instituto Nacional de Neurolog&#xed;a y Neurocirug&#xed;a, Secretar&#xed;a de Salud, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amigo</LastName><ForeName>Mary-Carmen</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-2255-3138</Identifier><AffiliationInfo><Affiliation>Rheumatology Department, Centro M&#xe9;dico ABC. Coordinator of Antiphospholipid Study Group of Mexican College of Rheumatology, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">accumulated damage</Keyword><Keyword MajorTopicYN="N">chronic damage</Keyword><Keyword MajorTopicYN="N">damage index in APS</Keyword><Keyword MajorTopicYN="N">health outcomes</Keyword><Keyword MajorTopicYN="N">thrombotic antiphospholipid syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>13</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>13</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40990115</ArticleId><ArticleId IdType="doi">10.1177/09612033251379310</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40974850</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-3278</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Rehabilitacion</Title><ISOAbbreviation>Rehabilitacion (Madr)</ISOAbbreviation></Journal><ArticleTitle>The burden of Wilson's disease: Insights into clinical, psychological, and functional dimensions.</ArticleTitle><Pagination><StartPage>100934</StartPage><MedlinePgn>100934</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rh.2025.100934</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0048-7120(25)00054-4</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Wilson's disease (WD) is a rare genetic disorder of copper metabolism with multi-systemic manifestations. Despite available treatment, patients often experience functional impairment. However, the relationship between clinical phenotype, mental status, and disability remains underexplored.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the associations between disease severity, cognitive performance, depressive symptoms, and functional disability in adults with WD using validated instruments.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this prospective, single-center cross-sectional study (2021-2023), 32 clinically stable WD patients followed at a tertiary neurology clinic were assessed with the WHODAS 2.0, GAS-WD, Mini-MoCA, and PHQ-9. Functional outcomes were evaluated using WHODAS 2.0 domains. Associations between clinical variables and scale scores were analyzed using non-parametric tests. Ethical approval (ref: 183-DEFI/165-CE) and informed consent were obtained.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants had a mean age of 39.8&#xb1;13.6 years; 56.3% were female. Median diagnostic delay was 1 year. Most had hepatic (56.3%) or neurological phenotype (37.5%). The WHODAS 2.0 participation domain was the most impaired (median=4.0, IQR 2-9). WHODAS scores correlated positively with GAS-WD scores (rs=0.77, p&lt;0.001) and PHQ-9 (rs=0.65, p&lt;0.001), and negatively with Mini-MoCA. No significant associations were found between diagnostic delay and disability. Stratified analysis revealed no statistically significant differences in participation across genders (p=0.83) or clinical subtypes (p=0.47).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Functional disability in WD is significantly associated with disease severity, cognitive deficits, and depressive symptoms, but not with gender or clinical subtype. WHODAS 2.0 is a feasible tool for comprehensive functional assessment in WD. Multidisciplinary approaches addressing mental and cognitive health are essential.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Sociedad Espa&#xf1;ola de Rehabilitaci&#xf3;n y Medicina F&#xed;sica. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Freixo Ribeiro</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Unidade Local de Sa&#xfa;de de Matosinhos, Matosinhos, Portugal. Electronic address: pedro.2.freixo@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moura</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Unidade Local de Sa&#xfa;de de Santo Ant&#xf3;nio, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos Silva</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pediatric Gastroenterology Unity, Department of Pediatrics, Unidade Local de Sa&#xfa;de de Santo Ant&#xf3;nio, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nery</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hepatic and Pancreatic Transplantation, Unidade Local de Sa&#xfa;de de Santo Ant&#xf3;nio, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pessegueiro Miranda</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hepatic and Pancreatic Transplantation, Unidade Local de Sa&#xfa;de de Santo Ant&#xf3;nio, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedroto</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Unidade Local de Sa&#xfa;de de Santo Ant&#xf3;nio, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Unidade Local de Sa&#xfa;de de Santo Ant&#xf3;nio, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gandara</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hepatic and Pancreatic Transplantation, Unidade Local de Sa&#xfa;de de Santo Ant&#xf3;nio, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maia</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Unidade Local de Sa&#xfa;de de Santo Ant&#xf3;nio, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Liver Unit/Department of Medicine, Unidade Local de Sa&#xfa;de de Tr&#xe1;s-os-Montes e Alto Douro, Vila Real, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hepatic and Pancreatic Transplantation, Unidade Local de Sa&#xfa;de de Santo Ant&#xf3;nio, Porto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magalh&#xe3;es</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Unidade Local de Sa&#xfa;de de Santo Ant&#xf3;nio, Porto, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rehabilitacion (Madr)</MedlineTA><NlmUniqueID>7802471</NlmUniqueID><ISSNLinking>0048-7120</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cognici&#xf3;n</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Depresi&#xf3;n</Keyword><Keyword MajorTopicYN="N">Depressive symptoms</Keyword><Keyword MajorTopicYN="N">Disability evaluation</Keyword><Keyword MajorTopicYN="N">Enfermedad de Wilson</Keyword><Keyword MajorTopicYN="N">Estado funcional</Keyword><Keyword MajorTopicYN="N">Participaci&#xf3;n social</Keyword><Keyword MajorTopicYN="N">Social participation</Keyword><Keyword MajorTopicYN="N">Wilson disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>21</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>21</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>20</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40974850</ArticleId><ArticleId IdType="doi">10.1016/j.rh.2025.100934</ArticleId><ArticleId IdType="pii">S0048-7120(25)00054-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40943286</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>17</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Association of Circulating miRNAs from the C19MC Cluster and IGF System with Macrosomia in Women with Gestational Diabetes Mellitus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8367</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms26178367</ELocationID><Abstract><AbstractText>Gestational diabetes mellitus (GDM) increases the risk of fetal overgrowth and macrosomia, yet the molecular mechanisms remain unclear. Emerging evidence implicates primate-specific placental microRNAs (miRNAs) from the C19MC cluster in modulating fetal growth via the insulin-like growth factor (IGF) axis. This study aimed to investigate the expression of circulating C19MC miRNAs in GDM pregnancies and their association with IGF axis biomarkers and birthweight outcomes. In this cross-sectional study, 158 pregnant women were stratified into normoglycemic pregnancies (<i>n</i> = 52), GDM with normal birthweight (<i>n</i> = 56), and GDM with large-for-gestational-age (LGA) newborns (<i>n</i> = 50). Plasma levels of 19 C19MC miRNAs and IGF-related proteins were measured. Associations between miRNAs, IGF axis components, and birthweight were analyzed using linear regression and correlation models adjusted for relevant covariates. Several miRNAs, including miR-516a-5p, miR-518d-3p, miR-521, and miR-525-3p, were differentially expressed in GDM, particularly in LGA cases. Strong correlations were observed, such as that of miR-516a-5p with IGFBP-5 (<i>r</i> = 0.705; <i>p</i> &lt; 0.001). Inverse associations with birthweight were found for miR-519b-3p, miR-518d-5p, and miR-520a-5p. Circulating C19MC miRNAs are dysregulated in GDM and correlate with IGF signaling and fetal growth, supporting their potential as early biomarkers for macrosomia risk in GDM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robledo-Clemente</LastName><ForeName>Magalhi Guadalupe</ForeName><Initials>MG</Initials><Identifier Source="ORCID">0009-0000-8661-2611</Identifier><AffiliationInfo><Affiliation>Unidad M&#xe9;dica de Alta Especialidad, Hospital de Gineco-Obstetricia No. 3 "Dr. V&#xed;ctor Manuel Espinosa de los Reyes S&#xe1;nchez", Centro M&#xe9;dico Nacional La Raza, Instituto Mexicano del Seguro Social, M&#xe9;xico City 02990, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva God&#xed;nez</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>PPCR Program, ECPE Department, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Escuela Nacional Colegio de Ciencias y Humanidades, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City 04510, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital General "Dra. Matilde Petra Montoya Lafragua", Instituto de Seguridad y Servicios Sociales para los Trabajadores del Estado, M&#xe9;xico City 13273, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xed;az-Vel&#xe1;zquez</LastName><ForeName>Mary Flor</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Unidad M&#xe9;dica de Alta Especialidad, Hospital de Gineco-Obstetricia No. 3 "Dr. V&#xed;ctor Manuel Espinosa de los Reyes S&#xe1;nchez", Centro M&#xe9;dico Nacional La Raza, Instituto Mexicano del Seguro Social, M&#xe9;xico City 02990, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendoza Reyes</LastName><ForeName>Edgar</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Unidad M&#xe9;dica de Alta Especialidad, Hospital de Gineco-Obstetricia No. 3 "Dr. V&#xed;ctor Manuel Espinosa de los Reyes S&#xe1;nchez", Centro M&#xe9;dico Nacional La Raza, Instituto Mexicano del Seguro Social, M&#xe9;xico City 02990, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xf3;mez Archilla</LastName><ForeName>Jos&#xe9; Dami&#xe1;n</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-9450-8731</Identifier><AffiliationInfo><Affiliation>Unidad M&#xe9;dica de Alta Especialidad, Hospital de Gineco-Obstetricia No. 3 "Dr. V&#xed;ctor Manuel Espinosa de los Reyes S&#xe1;nchez", Centro M&#xe9;dico Nacional La Raza, Instituto Mexicano del Seguro Social, M&#xe9;xico City 02990, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a Montes</LastName><ForeName>Lucia Daniela</ForeName><Initials>LD</Initials><Identifier Source="ORCID">0000-0002-5342-2421</Identifier><AffiliationInfo><Affiliation>Unidad M&#xe9;dica de Alta Especialidad, Hospital de Gineco-Obstetricia No. 3 "Dr. V&#xed;ctor Manuel Espinosa de los Reyes S&#xe1;nchez", Centro M&#xe9;dico Nacional La Raza, Instituto Mexicano del Seguro Social, M&#xe9;xico City 02990, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortez Ch&#xe1;vez</LastName><ForeName>Mauricio Ramiro</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Unidad M&#xe9;dica de Alta Especialidad, Hospital de Gineco-Obstetricia No. 3 "Dr. V&#xed;ctor Manuel Espinosa de los Reyes S&#xe1;nchez", Centro M&#xe9;dico Nacional La Raza, Instituto Mexicano del Seguro Social, M&#xe9;xico City 02990, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pe&#xf1;a-Cano</LastName><ForeName>Mar&#xed;a Isabel</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Hospital de Gineco-Obstetricia 221, Instituto Mexicano del Seguro Social, Toluca 50150, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saucedo</LastName><ForeName>Renata</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-5167-6156</Identifier><AffiliationInfo><Affiliation>Unidad de Investigaci&#xf3;n M&#xe9;dica en Enfermedades Endocrinas, Hospital de Especialidades "Dr. Bernardo Sep&#xfa;lveda Guti&#xe9;rrez", Centro M&#xe9;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, M&#xe9;xico City 06720, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074166">Circulating MicroRNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016640" MajorTopicYN="Y">Diabetes, Gestational</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005320" MajorTopicYN="Y">Fetal Macrosomia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074166" MajorTopicYN="Y">Circulating MicroRNA</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001724" MajorTopicYN="N">Birth Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013002" MajorTopicYN="Y">Somatomedins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C19MC microRNAs</Keyword><Keyword MajorTopicYN="N">IGF-binding proteins (IGFBPs)</Keyword><Keyword MajorTopicYN="N">epigenetic regulation</Keyword><Keyword MajorTopicYN="N">fetal macrosomia</Keyword><Keyword MajorTopicYN="N">gestational diabetes mellitus (GDM)</Keyword><Keyword MajorTopicYN="N">insulin-like growth factor (IGF) system</Keyword><Keyword MajorTopicYN="N">placental biomarkers</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>13</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>13</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40943286</ArticleId><ArticleId IdType="pmc">PMC12427975</ArticleId><ArticleId IdType="doi">10.3390/ijms26178367</ArticleId><ArticleId IdType="pii">ijms26178367</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Committee on Practice Bulletins&#x2014;Obstetrics ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet. Gynecol. 2018;131:e49&#x2013;e64. doi: 10.1097/AOG.0000000000002501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000002501</ArticleId><ArticleId IdType="pubmed">29370047</ArticleId></ArticleIdList></Reference><Reference><Citation>Plows J.F., Stanley J.L., Baker P.N., Reynolds C.M., Vickers M.H. The Pathophysiology of Gestational Diabetes Mellitus. Int. J. Mol. Sci. 2018;19:3342. doi: 10.3390/ijms19113342.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19113342</ArticleId><ArticleId IdType="pmc">PMC6274679</ArticleId><ArticleId IdType="pubmed">30373146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeting A., Wong J., Murphy H.R., Ross G.P. A Clinical Update on Gestational Diabetes Mellitus. Endocr. Rev. 2022;43:763&#x2013;793. doi: 10.1210/endrev/bnac003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endrev/bnac003</ArticleId><ArticleId IdType="pmc">PMC9512153</ArticleId><ArticleId IdType="pubmed">35041752</ArticleId></ArticleIdList></Reference><Reference><Citation>Napso T., Yong H.E.J., Lopez-Tello J., Sferruzzi-Perri A.N. The Role of Placental Hormones in Mediating Maternal Adaptations to Support Pregnancy and Lactation. Front. Physiol. 2018;9:1091. doi: 10.3389/fphys.2018.01091.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.01091</ArticleId><ArticleId IdType="pmc">PMC6108594</ArticleId><ArticleId IdType="pubmed">30174608</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo M.J., Parra H., Santeliz R., Bautista J., Luzardo E., Villasmil N., Mart&#xed;nez M.S., Chac&#xed;n M., Cano C., Checa-Ros A., et al. The Placental Role in Gestational Diabetes Mellitus: A Molecular Perspective. touchREVIEWS Endocrinol. 2024;20:10&#x2013;18. doi: 10.17925/EE.2024.20.1.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.17925/EE.2024.20.1.5</ArticleId><ArticleId IdType="pmc">PMC11132656</ArticleId><ArticleId IdType="pubmed">38812661</ArticleId></ArticleIdList></Reference><Reference><Citation>Taricco E., Radaelli T., Nobile de Santis M.S., Cetin I. Foetal and placental weights in relation to maternal characteristics in gestational diabetes. Placenta. 2003;24:343&#x2013;347. doi: 10.1053/plac.2002.0913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/plac.2002.0913</ArticleId><ArticleId IdType="pubmed">12657507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang F., Parker M., Cerda S., Pearson C., Fu L., Gillman M.W., Zuckerman B., Wang X. Placental weight mediates the effects of prenatal factors on fetal growth: The extent differs by preterm status. Obesity. 2013;21:609&#x2013;620. doi: 10.1002/oby.20254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.20254</ArticleId><ArticleId IdType="pmc">PMC3418379</ArticleId><ArticleId IdType="pubmed">23592670</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrar D., Simmonds M., Bryant M., Sheldon T.A., Tuffnell D., Golder S., Dunne F., Lawlor D.A. Hyperglycaemia and risk of adverse perinatal outcomes: Systematic review and meta-analysis. BMJ. 2016;354:i4694. doi: 10.1136/bmj.i4694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4694</ArticleId><ArticleId IdType="pmc">PMC5021824</ArticleId><ArticleId IdType="pubmed">27624087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis K.A., Chang L., Cheung J., Aouizerat B.E., Jelliffe-Pawlowski L.L., McLemore M.R., Piening B., Rand L., Ryckman K.K., Flowers E. Systematic review of transcriptome and microRNAome associations with gestational diabetes mellitus. Front. Endocrinol. 2022;13:971354. doi: 10.3389/fendo.2022.971354.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.971354</ArticleId><ArticleId IdType="pmc">PMC9871895</ArticleId><ArticleId IdType="pubmed">36704034</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguer-Dance M., Abu-Amero S., Al-Khtib M., Lef&#xe8;vre A., Coullin P., Moore G.E., Cavaill&#xe9; J. The primate-specific microRNA gene cluster (C19MC) is imprinted in the placenta. Hum. Mol. Genet. 2010;19:3566&#x2013;3582. doi: 10.1093/hmg/ddq272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq272</ArticleId><ArticleId IdType="pubmed">20610438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C., Zhang T., Shi Z., Ding H., Ling X. MicroRNA-518d regulates PPAR&#x3b1; protein expression in the placentas of females with gestational diabetes mellitus. Mol. Med. Rep. 2014;9:2085&#x2013;2090. doi: 10.3892/mmr.2014.2058.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2014.2058</ArticleId><ArticleId IdType="pubmed">24639097</ArticleId></ArticleIdList></Reference><Reference><Citation>Wommack J.C., Trzeciakowski J.P., Miranda R.C., Stowe R.P., Ruiz R.J. Micro RNA clusters in maternal plasma are associated with preterm birth and infant outcomes. PLoS ONE. 2018;13:e0199029. doi: 10.1371/journal.pone.0199029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0199029</ArticleId><ArticleId IdType="pmc">PMC6021076</ArticleId><ArticleId IdType="pubmed">29949620</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali A., Hadlich F., Abbas M.W., Iqbal M.A., Tesfaye D., Bouma G.J., Winger Q.A., Ponsuksili S. MicroRNA-mRNA Networks in Pregnancy Complications: A Comprehensive Downstream Analysis of Potential Biomarkers. Int. J. Mol. Sci. 2021;22:2313. doi: 10.3390/ijms22052313.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052313</ArticleId><ArticleId IdType="pmc">PMC7956714</ArticleId><ArticleId IdType="pubmed">33669156</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta M.B., Jansson T. Novel roles of mechanistic target of rapamycin signaling in regulating fetal growth. Biol. Reprod. 2019;100:872&#x2013;884. doi: 10.1093/biolre/ioy249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biolre/ioy249</ArticleId><ArticleId IdType="pmc">PMC6698747</ArticleId><ArticleId IdType="pubmed">30476008</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing J., Wang Y., Quan Y., Wang Z., Liu Y., Ding Z. Maternal obesity alters C19MC microRNAs expression profile in fetal umbilical cord blood. Nutr. Metab. 2020;17:52. doi: 10.1186/s12986-020-00475-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12986-020-00475-7</ArticleId><ArticleId IdType="pmc">PMC7339545</ArticleId><ArticleId IdType="pubmed">32655673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lappas M. Insulin-like growth factor-binding protein 1 and 7 concentrations are lower in obese pregnant women, women with gestational diabetes and their fetuses. J. Perinatol. Off. J. Calif. Perinat. Assoc. 2015;35:32&#x2013;38. doi: 10.1038/jp.2014.144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jp.2014.144</ArticleId><ArticleId IdType="pubmed">25078866</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Song L., Zhou L., Wu J., Sheng C., Chen H., Liu Y., Gao S., Huang W. A MicroRNA Signature in Gestational Diabetes Mellitus Associated with Risk of Macrosomia. Cell. Physiol. Biochem. 2015;37:243&#x2013;252. doi: 10.1159/000430349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000430349</ArticleId><ArticleId IdType="pubmed">26302821</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu G., Brki&#x107; J., Hayder H., Peng C. MicroRNAs in Human Placental Development and Pregnancy Complications. Int. J. Mol. Sci. 2013;14:5519&#x2013;5544. doi: 10.3390/ijms14035519.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms14035519</ArticleId><ArticleId IdType="pmc">PMC3634453</ArticleId><ArticleId IdType="pubmed">23528856</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsochandaridis M., Nasca L., Toga C., Levy-Mozziconacci A. Circulating microRNAs as clinical biomarkers in the predictions of pregnancy complications. BioMed Res. Int. 2015;2015:294954. doi: 10.1155/2015/294954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/294954</ArticleId><ArticleId IdType="pmc">PMC4325204</ArticleId><ArticleId IdType="pubmed">25699269</ArticleId></ArticleIdList></Reference><Reference><Citation>Forbes K., Westwood M. The IGF axis and placental function. a mini review. Horm. Res. 2008;69:129&#x2013;137. doi: 10.1159/000112585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000112585</ArticleId><ArticleId IdType="pubmed">18219215</ArticleId></ArticleIdList></Reference><Reference><Citation>Sferruzzi-Perri A.N., Owens J.A., Pringle K.G., Roberts C.T. The neglected role of insulin-like growth factors in the maternal circulation regulating fetal growth. Pt 1J. Physiol. 2011;589:7&#x2013;20. doi: 10.1113/jphysiol.2010.198622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2010.198622</ArticleId><ArticleId IdType="pmc">PMC3021777</ArticleId><ArticleId IdType="pubmed">20921199</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Ma Q., Wang Y., Tang Z. Clinical application of exosomes and circulating microRNAs in the diagnosis of pregnancy complications and foetal abnormalities. J. Transl. Med. 2020;18:32. doi: 10.1186/s12967-020-02227-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02227-w</ArticleId><ArticleId IdType="pmc">PMC6975063</ArticleId><ArticleId IdType="pubmed">31969163</ArticleId></ArticleIdList></Reference><Reference><Citation>Alekseenkova E.N., Babakov V.N., Selkov S.A., Di Renzo G.C., Kogan I.Y., Kapustin R.V. Maternal insulin-like growth factors and insulin-like growth factor-binding proteins for macrosomia prediction in diabetic and nondiabetic pregnancy: A prospective study. Int. J. Gynecol. Obstet. 2023;162:605&#x2013;613. doi: 10.1002/ijgo.14696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijgo.14696</ArticleId><ArticleId IdType="pubmed">36708099</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-Prieto D.M., Ospina-Prieto S., Chaiwangyen W., Schoenleben M., Markert U.R. Pregnancy-associated miRNA-clusters. J. Reprod. Immunol. 2013;97:51&#x2013;61. doi: 10.1016/j.jri.2012.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jri.2012.11.001</ArticleId><ArticleId IdType="pubmed">23432872</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo S.-S., Ishibashi O., Ishikawa G., Ishikawa T., Katayama A., Mishima T., Takizawa T., Shigihara T., Goto T., Izumi A., et al. Human villous trophoblasts express and secrete placenta-specific microRNAs into maternal circulation via exosomes. Biol. Reprod. 2009;81:717&#x2013;729. doi: 10.1095/biolreprod.108.075481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1095/biolreprod.108.075481</ArticleId><ArticleId IdType="pubmed">19494253</ArticleId></ArticleIdList></Reference><Reference><Citation>Donker R.B., Mouillet J.F., Chu T., Hubel C.A., Stolz D.B., Morelli A.E., Sadovsky Y. The expression profile of C19MC microRNAs in primary human trophoblast cells and exosomes. Mol. Hum. Reprod. 2012;18:417&#x2013;424. doi: 10.1093/molehr/gas013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molehr/gas013</ArticleId><ArticleId IdType="pmc">PMC3389496</ArticleId><ArticleId IdType="pubmed">22383544</ArticleId></ArticleIdList></Reference><Reference><Citation>Alekseenkova E.N., Selkov S.A., Kapustin R.V. Fetal growth regulation via insulin-like growth factor axis in normal and diabetic pregnancy. J. Perinat. Med. 2022;50:947&#x2013;960. doi: 10.1515/jpm-2021-0510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jpm-2021-0510</ArticleId><ArticleId IdType="pubmed">35363447</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Juarez L.A., Gallardo-Rinc&#xf3;n H., Saucedo-Mart&#xed;nez R., M&#xfa;jica-Rosales R., Reyes-Mu&#xf1;oz E., &#xc1;lvarez-Hern&#xe1;ndez D.-A., Tapia-Conyer R. A strategic framework for managing gestational diabetes in Mexico. Glob. Health Res. Policy. 2025;10:12. doi: 10.1186/s41256-025-00406-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41256-025-00406-0</ArticleId><ArticleId IdType="pmc">PMC11871795</ArticleId><ArticleId IdType="pubmed">40022186</ArticleId></ArticleIdList></Reference><Reference><Citation>Damm P., Houshmand-Oeregaard A., Kelstrup L., Lauenborg J., Mathiesen E.R., Clausen T.D. Gestational diabetes mellitus and long-term consequences for mother and offspring: A view from Denmark. Diabetologia. 2016;59:1396&#x2013;1399. doi: 10.1007/s00125-016-3985-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-016-3985-5</ArticleId><ArticleId IdType="pubmed">27174368</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Su R., Qin S., Wei Y. High glucose increases IGF-2/H19 expression by changing DNA methylation in HTR8/SVneo trophoblast cells. Placenta. 2022;118:32&#x2013;37. doi: 10.1016/j.placenta.2021.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.placenta.2021.12.022</ArticleId><ArticleId IdType="pubmed">35007927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali A., Bouma G.J., Anthony R.V., Winger Q.A. The Role of LIN28-let-7-ARID3B Pathway in Placental Development. Int. J. Mol. Sci. 2020;21:3637. doi: 10.3390/ijms21103637.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21103637</ArticleId><ArticleId IdType="pmc">PMC7279312</ArticleId><ArticleId IdType="pubmed">32455665</ArticleId></ArticleIdList></Reference><Reference><Citation>Filardi T., Catanzaro G., Grieco G.E., Splendiani E., Trocchianesi S., Santangelo C., Brunelli R., Guarino E., Sebastiani G., Dotta F., et al. Identification and Validation of miR-222-3p and miR-409-3p as Plasma Biomarkers in Gestational Diabetes Mellitus Sharing Validated Target Genes Involved in Metabolic Homeostasis. Int. J. Mol. Sci. 2022;23:4276. doi: 10.3390/ijms23084276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23084276</ArticleId><ArticleId IdType="pmc">PMC9028517</ArticleId><ArticleId IdType="pubmed">35457094</ArticleId></ArticleIdList></Reference><Reference><Citation>Thamotharan S., Ghosh S., James-Allan L., Lei M.Y.Y., Janzen C., Devaskar S.U. Circulating extracellular vesicles exhibit a differential miRNA profile in gestational diabetes mellitus pregnancies. PLoS ONE. 2022;17:e0267564. doi: 10.1371/journal.pone.0267564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0267564</ArticleId><ArticleId IdType="pmc">PMC9132306</ArticleId><ArticleId IdType="pubmed">35613088</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44((Suppl. 1)):S15&#x2013;S33. doi: 10.2337/dc21-S002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc21-S002</ArticleId><ArticleId IdType="pubmed">33298413</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., Mueller R., Nolan T., Pfaffl M.W., Shipley G.L., et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009;55:611&#x2013;622. doi: 10.1373/clinchem.2008.112797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2008.112797</ArticleId><ArticleId IdType="pubmed">19246619</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>